Allspring Global Investments
KALV

Allspring Global Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Allspring Global Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,600
Closed -$23K – 2812
2022
Q1 		$23K Sell
1,600
-43
-3% -$618 ﹤0.01% 2929
2021
Q4 		$21K Buy
+1,643
New +$26.2K ﹤0.01% 2898

Other funds holding KALV

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Allspring Global Investments's KALV Position: Q2 2022 in Review

Allspring Global Investments sold out of KalVista Pharmaceuticals (KALV) in Q2 2022, closing a stake of 1,600 shares — an estimated $23K sold.

Allspring Global Investments first reported a position in KALV in Q4 2021 and held it in 2 quarters. The position peaked at $23K in Q1 2022. 91 funds tracked by Wall St. Rank hold KALV as of Q2 2022.

  • Allspring Global Investments reported no remaining KalVista Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 1,600 KalVista Pharmaceuticals shares in Q2 2022, an estimated $23K.
  • Allspring Global Investments first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's KalVista Pharmaceuticals position peaked at $23K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.